News | November 14, 2025
Pfizer completes up to $10 billion acquisition of Metsera
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
